Premium
Semen analysis and treatment risk factors in long‐term survivors of childhood cancer
Author(s) -
Kruseová Jarmila,
Černíková Jelena,
Zámečníková Marina,
Hřivnová Lucie,
Koloušková Stanislava,
Čepelová Michaela,
Kabíčková Edita,
Čapek Václav,
Lukš Aleš,
Eckschlager Tomáš
Publication year - 2021
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.13853
Subject(s) - semen quality , semen analysis , semen , medicine , sperm , infertility , cancer , physiology , sperm motility , male infertility , gynecology , oncology , andrology , pregnancy , biology , genetics
The objective of this study was to compare semen quality (sperm density, progressive motility and spermia) between long‐term childhood cancer survivors and a control group of males. The second objective was to correlate the semen analysis of the survivors with cancer treatment and endocrine status. The semen quality of 143 survivors (median age, 23.6 years) was compared to 200 men (median age, 27.9 years) who had not been diagnosed with cancer. The cancer‐related risk factors and gonadotrophin levels were compared. Overall, 65% of the survivors had abnormal semen analysis compared to 26.5% of the controls ( p < 0.0001). Survivors with nonaspermia had lower sperm density than the controls ( p < 0.001). Other observed correlations were not significant. Survivors who were treated with alkylating agents were more likely to have abnormal semen analysis ( p < 0.008). Follicle‐stimulating hormone and luteinising hormone levels were significantly elevated ( p < 0.0001) in survivors with abnormal semen analysis. The semen quality parameters, except for low sperm density, did not differ in survivors with nonaspermia compared to the controls. The risk factors included treatment with alkylating agents. Elevated gonadotrophin levels correlated with abnormal semen analysis. All cancer survivors should be made aware of the possibility of suffering from cancer treatment‐related infertility.